
To define the zzso doses zzso and zzso zzso zzso of zzso given as a zzso infusion daily for 5 days, in patients with solid tumors and with acute zzso 

The initial part of the study defined the zzso and zzso in solid zzso The second part of the study defined the zzso and zzso in acute zzso 

The starting dose of zzso (15 zzso was zzso requiring several dose zzso to 2 zzso the dose suggested for phase II studies in solid zzso zzso escalation in acute leukemia started at zzso zzso with several zzso to 55 zzso The zzso was zzso zzso at 55 zzso The recommended dose for acute leukemia phase II studies was 40 zzso Among 32 treated patients with acute zzso two achieved a complete response and three had a zzso complete response without zzso recovery zzso zzso for an overall response rate of zzso At 40 zzso the median plasma zzso level was zzso zzso zzso zzso zzso to zzso zzso zzso zzso zzso zzso Cellular and plasma zzso studies suggested dose zzso but showed a wide variation in zzso zzso of zzso zzso 

This phase I study defined the following two zzso for zzso given as a zzso infusion daily for 5 days: 2 zzso for solid tumors, the zzso being zzso and 40 zzso for acute zzso the zzso being zzso zzso activity was observed in acute zzso 

